Objective
Healthcare-associated infections (HAIs) in intensive care units (ICUs) remain a major clinical and societal challenge. Up to 40% of ICU patients develop at least one infection, and mortality rates are often above 30%. The situation is further aggravated by the rise of antimicrobial resistance (AMR) and the declining effectiveness of existing antibiotics. Gram-negative pathogens are recognised by WHO as critical priority threats, with resistance to antibiotics projected to more than double by 2035. Current preventive strategies are insufficient and underscore the urgent need for novel biotech-based therapies.
DITRAP introduces RA0127, a first-in-class soluble glycopolymer that selectively removes natural anti-αGal antibodies. These antibodies, paradoxically, enhance Gram-negative infections and create an “immune trap” in critically ill patients. By disarming this trap, RA0127 strengthens host immunity without immunosuppression, restoring the body’s ability to clear even multidrug-resistant pathogens. A completed Phase 1 trial confirmed safety and demonstrated over 60% reduction of target antibodies after a single low dose, providing a strong foundation for Phase 2 evaluation.
To maximise precision and responsible clinical application, DITRAP integrates an AI-based stratification tool that identifies high-risk patients within 48 hours of admission and enables targeted therapy. Alongside, comprehensive health economic modelling and Health Technology Assessment (HTA) will ensure robust evaluation of clinical benefit, cost-effectiveness and adoption across European healthcare systems.
The consortium unites leading SMEs, clinical and academic partners with complementary expertise and are supported by the European Society of Anaesthesiology and Intensive Care (ESAIC). DITRAP directly addresses Horizon Europe’s objective to boost translation of biotech research into innovative therapies, advancing Europe’s fight against AMR and tackling an urgent public health priority.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs antibiotics
- medical and health sciences clinical medicine anaesthesiology
You need to log in or register to use this function
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
HORIZON.2.1 - Health
MAIN PROGRAMME
See all projects funded under this programme -
HORIZON.2.1.5 - Tools, Technologies and Digital Solutions for Health and Care, including personalised medicine
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
HORIZON-RIA - HORIZON Research and Innovation Actions
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) HORIZON-HLTH-2025-01
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
08193 CERDANYOLA DEL VALLES
Spain
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.